PDCD1 and hepatocellular carcinoma: Nivolumab stands out in this regard as a fully human IgG4 monoclonal antibody (mAb) that inhibits PD-1 and increases the activity of effector T-cells, allowing them to recognize and destroy cancer cells in the HCC microenvironment [25].